A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
NCT ID: NCT00700180
Last Updated: 2014-09-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
303 participants
INTERVENTIONAL
2008-09-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
NCT00776698
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
NCT00451906
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
NCT00404703
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
NCT00773188
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
NCT01333007
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
bevacizumab [Avastin]
7.5mg/kg iv on day 1 of each 3 week cycle
Carboplatin-based chemotherapy
As prescribed
2
bevacizumab [Avastin]
15mg/kg iv on day 1 of each 3 week cycle
Carboplatin-based chemotherapy
As prescribed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bevacizumab [Avastin]
7.5mg/kg iv on day 1 of each 3 week cycle
bevacizumab [Avastin]
15mg/kg iv on day 1 of each 3 week cycle
Carboplatin-based chemotherapy
As prescribed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* locally advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC);
* \>=1 measurable tumor lesion;
* ECOG performance status 0-1.
Exclusion Criteria
* evidence of CNS metastases;
* history of grade 2 or higher hemoptysis;
* evidence of tumor invading or abutting major blood vessels;
* malignancies other than NSCLC within 5 years prior to randomization, other than adequately treated cancer in situ of cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS;
* clinically significant cardiovascular disease;
* current or recent use of aspirin (\>325mg/day) or full dose anticoagulants or thrombolytic agents for therapeutic purposes.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Leonards, New South Wales, Australia
Adelaide, South Australia, Australia
Adelaide, South Australia, Australia
Box Hill, Victoria, Australia
Fitzroy, Victoria, Australia
Antwerp, , Belgium
Liège, , Belgium
Vancouver, British Columbia, Canada
Toronto, Ontario, Canada
Ostrava, , Czechia
Prague, , Czechia
Odense, , Denmark
Paris, , France
Rouen, , France
Bad Berka, , Germany
Großhansdorf, , Germany
Hamburg, , Germany
Oldenburg, , Germany
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Budapest, , Hungary
Edelény, , Hungary
Sopron, , Hungary
Szombathely, , Hungary
Törökbálint, , Hungary
Milan, , Italy
Milan, , Italy
Orbassano, , Italy
Roma, , Italy
Enschede, , Netherlands
Hoorn, , Netherlands
Nieuwegein, , Netherlands
Rotterdam, , Netherlands
The Hague, , Netherlands
Poznan, , Poland
Warsaw, , Poland
Zabrze, , Poland
Arkhangelsk, , Russia
Chelyabinsk, , Russia
Kazan', , Russia
Kazan', , Russia
Krasnodar, , Russia
Krasnodar, , Russia
Moscow, , Russia
Moscow, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Seville, Sevilla, Spain
Valencia, Valencia, Spain
Valencia, Valencia, Spain
Barakaldo, Vizcaya, Spain
Changhua, , Taiwan
Taichung, , Taiwan
Taichung, , Taiwan
Taichung, , Taiwan
Taipei, , Taiwan
Aberdeen, , United Kingdom
Chelmsford, , United Kingdom
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-000662-23
Identifier Type: -
Identifier Source: secondary_id
BO21015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.